Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment option even in the first-line setting. ICIs can block inhibitory pathways that restrain the immune response against cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Sun Min, Hong, Min Hee, Kim, Hye Ryun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Immunologists 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049584/
https://www.ncbi.nlm.nih.gov/pubmed/32158598
http://dx.doi.org/10.4110/in.2020.20.e10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049584/
https://www.ncbi.nlm.nih.gov/pubmed/32158598
http://dx.doi.org/10.4110/in.2020.20.e10

Ejemplares similares